VOYAGER THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.62 USD | +2.70% |
|
+1.60% | -9.72% |
| Apr. 02 | Voyager Therapeutics, Inc. Appoints Robin Swartz as Principal Accounting Officer | CI |
| Apr. 02 | Voyager Therapeutics, Inc. Announces CFO Changes | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 517.2 | 267.9 | 102.9 | 235.5 | 371.3 | 414.4 | - | - |
| Enterprise Value (EV) 1 | 235.6 | 86.74 | -14.57 | 116.7 | 140.4 | 98.24 | 41.19 | -105.5 |
| P/E ratio | -11.5 x | 7.3 x | -1.43 x | -5.04 x | 2.84 x | -4.24 x | -4.34 x | -5.23 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 4.95 x | 1.57 x | 2.75 x | 5.76 x | 1.49 x | 10.7 x | 8.1 x | 7.47 x |
| EV / Revenue | 2.26 x | 0.51 x | -0.39 x | 2.85 x | 0.56 x | 2.53 x | 0.8 x | -1.9 x |
| EV / EBITDA | -4.82 x | 2.78 x | 0.21 x | -2.61 x | 1.11 x | -1.02 x | -0.45 x | 0.99 x |
| EV / FCF | 5.73 x | -0.8 x | 0.26 x | -7.78 x | 1.88 x | -1.49 x | -0.64 x | 1.19 x |
| FCF Yield | 17.5% | -125% | 378% | -12.9% | 53.2% | -67.1% | -157% | 83.7% |
| Price to Book | 5.17 x | 1.73 x | 1.08 x | 3.99 x | 1.54 x | 1.46 x | 1.53 x | 1.2 x |
| Nbr of stocks (in thousands) | 37,073 | 37,466 | 37,957 | 38,607 | 43,995 | 54,388 | - | - |
| Reference price 2 | 13.95 | 7.150 | 2.710 | 6.100 | 8.440 | 7.620 | 7.620 | 7.620 |
| Announcement Date | 3/3/20 | 2/25/21 | 3/8/22 | 3/7/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 104.4 | 171.1 | 37.42 | 40.91 | 250 | 38.84 | 51.19 | 55.45 |
| EBITDA 1 | -48.91 | 31.2 | -68.45 | -44.65 | 126.5 | -96.75 | -90.58 | -106.3 |
| EBIT 1 | -51.68 | 27.38 | -73.62 | -50.84 | 122 | -111.5 | -118.9 | -120 |
| Operating Margin | -49.51% | 16% | -196.76% | -124.27% | 48.8% | -286.99% | -232.3% | -216.44% |
| Earnings before Tax (EBT) 1 | -43.6 | 36.74 | -71.2 | -46.39 | 133.7 | -98.38 | -105.8 | -108.1 |
| Net income 1 | -43.6 | 36.74 | -71.2 | -46.41 | 132.3 | -98.38 | -105.8 | -108.1 |
| Net margin | -41.76% | 21.47% | -190.29% | -113.45% | 52.93% | -253.27% | -206.66% | -194.9% |
| EPS 2 | -1.210 | 0.9800 | -1.890 | -1.210 | 2.970 | -1.796 | -1.755 | -1.456 |
| Free Cash Flow 1 | 41.12 | -108.8 | -55.13 | -15 | 74.66 | -65.92 | -64.49 | -88.3 |
| FCF margin | 39.39% | -63.59% | -147.36% | -36.67% | 29.86% | -169.71% | -125.99% | -159.25% |
| FCF Conversion (EBITDA) | - | - | - | - | 59.04% | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | 56.42% | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/3/20 | 2/25/21 | 3/8/22 | 3/7/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1.482 | 28.07 | 0.658 | 0.712 | 41.09 | -1.55 | 150.5 | 4.853 | 4.614 | 90.06 | 9.48 | 7.589 | 7.646 | 8.428 | 8.705 |
| EBITDA 1 | -23.92 | 7.184 | -18.54 | -18.16 | 15.78 | -23.73 | 124 | -24.34 | -28.56 | 55.4 | -23.69 | -23.12 | -23.73 | -23.5 | - |
| EBIT 1 | -25.15 | 5.702 | -21.35 | -19.37 | 14.44 | -24.56 | 122.9 | -25.43 | -29.51 | 54.06 | -26.83 | -29.33 | -30.8 | -31.5 | -43.13 |
| Operating Margin | -1,696.76% | 20.31% | -3,244.68% | -2,720.08% | 35.15% | 1,584.71% | 81.66% | -523.92% | -639.51% | 60.03% | -282.97% | -386.5% | -402.81% | -373.79% | -495.52% |
| Earnings before Tax (EBT) 1 | -25.14 | 5.708 | -21.32 | -19.09 | 17.62 | -23.61 | 124.7 | -22.15 | -26.08 | 57.22 | -23.8 | -25.95 | -27.49 | -28.33 | -40.06 |
| Net income 1 | -25.14 | 5.708 | -21.32 | -19.09 | 17.62 | -23.63 | 124 | -22.21 | -25.9 | 56.4 | -23.8 | -25.95 | -27.49 | -28.33 | -40.06 |
| Net margin | -1,696.15% | 20.33% | -3,239.97% | -2,680.76% | 42.9% | 1,524.26% | 82.43% | -457.61% | -561.36% | 62.62% | -251.06% | -341.89% | -359.57% | -336.09% | -460.17% |
| EPS 2 | -0.6700 | 0.1500 | -0.5600 | -0.5000 | 0.4500 | -0.6100 | 2.940 | -0.5100 | -0.5900 | 1.250 | -0.4399 | -0.4730 | -0.4931 | -0.5076 | -0.5875 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/2/21 | 3/8/22 | 5/4/22 | 8/4/22 | 11/8/22 | 3/7/23 | 5/9/23 | 8/3/23 | 11/6/23 | 2/28/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 282 | 181 | 117 | 119 | 231 | 316 | 373 | 520 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | 41.1 | -109 | -55.1 | -15 | 74.7 | -65.9 | -64.5 | -88.3 |
| ROE (net income / shareholders' equity) | -59.7% | 28.9% | -57.1% | -60.2% | 89.6% | -30% | -22.4% | -27.3% |
| ROA (Net income/ Total Assets) | -16.4% | - | - | - | - | - | - | - |
| Assets 1 | 265.9 | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 2.700 | 4.130 | 2.510 | 1.530 | 5.490 | 5.210 | 4.970 | 6.360 |
| Cash Flow per Share 2 | 1.360 | -2.590 | -1.420 | -0.3300 | 1.810 | -1.740 | -0.1500 | -1.170 |
| Capex 1 | 7.55 | 12.1 | 1.61 | 2.49 | 3.26 | 5.41 | 5.41 | 7.6 |
| Capex / Sales | 7.23% | 7.07% | 4.3% | 6.09% | 1.3% | 13.92% | 10.56% | 13.71% |
| Announcement Date | 3/3/20 | 2/25/21 | 3/8/22 | 3/7/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
7.62
USD
Average target price
17.78
USD
Spread / Average Target
+133.30%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -9.72% | 414M | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- VYGR Stock
- Financials Voyager Therapeutics, Inc.
